Investor Relations

Cyxone is a Swedish biotech company that develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders in convenient administration forms.

With three unique projects, all developing towards important and potentially value-creating milestones, Cyxone is well positioned to deliver consequential benefits for patients, the health care system as well as for its shareholders. Cyxone’s goal is to out-license projects to strong partners after Phase 2 clinical trials to maximize their potential.

Investor Relations contact
Tara Heitner, CEO
tara.heitner@cyxone.com

Latest Presentations

Interview with CEO Tara Heitner September 15, 2020

15 September 2020

Småbolagsjakten Live (in swedish)

14 November 2018

Analyst Group interviews CEO Kjell G Stenberg (in swedish)

12 October 2018

Latest Press Release

Record date for the distribution of warrants of series TO4 to current shareholders is set to November 19, 2020

November 16, 2020 14:59 (CET)

Regulatory
On November 10 2020, the board of directors of Cyxone AB (publ), (“Cyxone” or the “Company”) decided to carry out a Directed Issue (the “Directed Issue”), and to issue warrants of series TO4 to the current shareholders of Cyxone who on the record date holds shares in the Company. The warrants will, to some extent, compensate the current shareholders in the Company for the dilution in the Directed Issue.
Read more

Financial Calendar

Silent period Q4, 2020

Start date: 13 January 2021

End date: 12 February 2021

The year-end report will be published on 12 February 2021 and the silent period starts 13 January 2021.

Year-end Report 2020

Date: 12 February 2021